## CLX: The Clorox Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 3.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($100.21)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 3, Bearish: 0)

**1. Norges Bank Makes New Investment in The Clorox Company $CLX**
- Source: MarketBeat | 20251203T121232 | Somewhat-Bearish | Relevance: 100%
- Norges Bank has made a significant new investment in The Clorox Company, purchasing over 1.5 million shares valued at approximately $190.4 million during Q2, representing about 1.29% of the company. This comes as Clorox reported Q2 earnings of $0.85 EPS, exceeding expectations, but with an 18.9% revenue decline year-over-year and forward guidance below analyst estimates. The company declared a quarterly dividend of $1.24, resulting in a 4.7% yield, while analysts generally hold a "Reduce" rating with an average target price of $125.69.

**2. Korea Investment CORP Grows Stake in The Clorox Company $CLX**
- Source: MarketBeat | 20251202T110417 | Somewhat-Bearish | Relevance: 100%
- Korea Investment CORP significantly increased its stake in The Clorox Company by 324.7% in Q2 2025, now owning 117,570 shares valued at approximately $14.12 million. Despite this increased institutional interest, analysts have recently issued "Reduce" ratings with an average price target of $125.69, following mixed Q3 results where EPS beat estimates but revenue declined. The company also declared a quarterly dividend of $1.24 per share.

**3. Clorox: A Dividend Champion Facing Headwinds, But Still A Buy (NYSE:CLX)**
- Source: Seeking Alpha | 20251202T093900 | Bullish | Relevance: 100%
- Clorox is positioned as a market leader with a 48-year dividend growth streak and a nearly 5% yield. Despite recent setbacks like revenue declines due to an ERP transition, cyberattack, and inflation, the company's IGNITE plan aims for 3-5% sales growth and improved margins. With acceptable dividend safety metrics and an undervaluation at ~$108/share compared to a fair value of $119.80, Clorox is recommended as a buy for dividend growth portfolios.

**4. The Clorox Company $CLX Shares Sold by Skandinaviska Enskilda Banken AB publ**
- Source: MarketBeat | 20251201T115042 | Neutral | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ decreased its stake in The Clorox Company (NYSE:CLX) by 30.3% in Q2, while other major institutions like Norges Bank, Hsbc Holdings PLC, and Nuance Investments LLC significantly increased their holdings. Clorox reported quarterly EPS of $0.85, exceeding estimates, but revenue declined by 18.9% year-over-year. The company declared a quarterly dividend of $1.24, and analysts maintain a "Reduce" consensus rating with a target price of $125.69.

**5. Glad launches new musical number "I Love Trash — The Remix feat. Oscar the Grouch"**
- Source: The Clorox Company | 20251203T193607 | Bullish | Relevance: 100%
- Glad has launched a new musical campaign featuring Oscar the Grouch, reinterpreting the classic song "I Love Trash — The Remix." This campaign aims to show consumers that messes are manageable with Glad products, transforming the conversation about trash into something humorous. The initiative includes various digital content, limited-edition Oscar-inspired merchandise, and a social activation.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-04 | Citigroup | $120 | $130 | -8% |
| 2025-11-04 | Morgan Stanley | $125 | $137 | -9% |
| 2025-11-04 | Wells Fargo | $117 | $125 | -6% |
| 2025-11-04 | JP Morgan | $120 | $127 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-04 | Citigroup | main | Neutral |
| 2025-11-04 | Morgan Stanley | main | Equal-Weight |
| 2025-11-04 | Wells Fargo | main | Equal-Weight |
| 2025-11-04 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($10.20M) |
| Sells | 11 ($0.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (-0.7%)
- Blackrock Inc.: 8.5% (-1.2%)
- State Street Corpora: 6.9% (+3.5%)
- Invesco Ltd.: 3.3% (+23.1%)
- Morgan Stanley: 2.6% (+18.3%)

### Key Risks

1. Valuation stretched: PEG 3.2x requires aggressive growth execution.
2. Long-term trend broken: trading 17.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.19 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 44%, ROA 12%). Analyst sentiment negative (4 target cuts vs 0 raises). Insider buying signal ($10.2M), management confidence. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.0B |
| Beta | 0.57 |
| 52W Range | $96.66 - $164.41 |
| Short Interest | 6.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.19 |
| Forward P/E | 15.6 |
| Current P/E | 17.6 |
| YoY Growth | 12.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.3% to -1.4% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.82x), long-term trend not supportive. MACD histogram positive (0.88), confirming momentum. RSI neutral at 43. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.43% (CS: 37) | Neutral |
| RSI_14 | 42.8 | Neutral |
| MACD Histogram | 0.88 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 0.931x | Below |
| vs SMA200 | 0.822x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $105.17
- **Stop Loss:** $100.21 (4.7% risk)
- **Target:** $110.13 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 191
- **Position Value:** $20,087.47
- **Portfolio %:** 20.09%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-03 (Est: $1.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.78 | $0.85 | +9.2% |
| 2025Q2 | $2.21 | $2.87 | +29.8% |
| 2025Q1 | $1.56 | $1.45 | -6.9% |
| 2024Q4 | $1.40 | $1.55 | +10.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*